We sought to evaluate the association between cholesteryl ester transfer protein (CETP) genotypes and the risk of future cardiovascular mortality in patients with coronary artery disease (CAD). BACKGROUND Polymorphisms of the CETP gene influence CETP activity and high-density lipoprotein (HDL) cholesterol concentration and might affect the long-term prognosis and response to statin therapy in patients with CAD.
The inverse relationship between serum high-density lipoprotein (HDL) cholesterol and ischemic heart disease has increasingly been recognized in numerous clinical and epidemiologic studies (1) . Cholesteryl ester transfer protein
See page 1990
(CETP) distributes cholesteryl esters and triglycerides between lipoproteins and is a key enzyme in reverse cholesterol transport (RCT) and HDL metabolism (2, 3) . However, whether CETP acts in a pro-or anti-atherogenic fashion still remains controversial (4 -6).
A major deficiency of CETP activity due to rare genetic mutations has been reported to be associated with an increased prevalence of coronary artery disease (CAD) in Japanese men, despite high levels of HDL cholesterol (7) . A common polymorphism of the CETP gene located in intron 1 (TaqIB) has consistently been shown to influence CETP activity and HDL cholesterol levels (8 -12) . However, this polymorphism is unlikely to be functional by itself and rather reflects the effect of one or several functional variants of the CETP gene (13) . In particular, the TaqIB polymorphism was found to be in nearly complete association with the CETP/C-629A polymorphism located in the promoter (13) , which was further shown to influence gene expression and CETP activity (14) .
Patients with low plasma HDL cholesterol receive a clinical benefit from statin therapy (15) . Because of the strong impact of CETP gene variations on HDL cholesterol, it might be hypothesized that CETP polymorphisms modulate the effect of statin therapy on HDL cholesterol and possibly on CAD risk. Supporting this hypothesis, it was recently shown that the TaqIB polymorphism was associated with different effects of pravastatin treatment on progression of coronary atherosclerosis (16) .
In light of the previous findings, the present study was primarily aimed at investigating whether CETP gene polymorphisms influence CETP activity, HDL cholesterol concentrations, and long-term prognosis in a large, prospective cohort of German patients with CAD. A secondary hypothesis investigated was whether CETP polymorphisms might modulate the clinical benefits of statin therapy on future CAD events. Among the different polymorphisms that were previously described in the CETP gene (14), we selected for this study the functional promoter CETP/C-629A polymorphism and the exonic CETP/I405V polymorphism, because they had been previously shown to have the strongest influence on CETP activity and HDL cholesterol (14) .
METHODS

Study participants.
A detailed description of the design of the AtheroGene Study has been outlined previously (17) . Briefly, between November 1996 and June 2000, 1,303 patients who underwent coronary angiography at the Department of Medicine II of the Johannes GutenbergUniversity Mainz or the Bundeswehrzentralkrankenhaus Koblenz and who had at least one stenosis Ͼ30% diagnosed in a major coronary artery were enrolled in a cardiovascular registry. Of the patients, 910 (70%) presented with stable angina and 393 (30%) presented with an acute coronary syndrome; in the latter group, 336 had unstable angina by the Braunwald classification (class B or C) and 57 had an acute myocardial infarction (MI) within the previous 48 h. The present study was based on 1,211 patients (92.9%) who were genotyped for both the CETP/C-629A and CETP/ I405V polymorphisms. Missing genotype information was due to technical difficulties or a lack of deoxyribonucleic acid. Evaluation of end points. A total of 1,206 (99.6%) of 1,211 patients were followed up during a median period of 4.1 years (maximum 5.2 years). Patients either presented at our clinic (87.2%) or a telephone interview was performed by trained medical staff. Follow-up information was obtained on death from cardiovascular causes, including fatal MI, sudden cardiac death, and death from vascular causes (n ϭ 82); death from causes not related to heart disease (n ϭ 25); nonfatal MI (n ϭ 50); and nonfatal stroke (n ϭ 31).
Information on the cause of death or clinical events was obtained from hospital or general practitioner charts. Statin prescription status was obtained by a questionnaire at study enrollment and was available for all study subjects. A total of 411 patients (34%) had been receiving treatment with one of six different statins at study entry (immediately before coronary angiography) and as discharge medication and continued to take this medication at the time of follow-up (atorvastatin 24.7%, cerivastatin 19.3%, pravastatin 18.4%, simvastatin 17.3%, lovastatin 17.1%, or fluvastatin 3.2%). All patients who received statin therapy as discharge medication but did not continue to take it during follow-up were identified as "dropouts" and considered in the group of "no statin medication." Use of statin therapy at the end of follow-up was verified by a questionnaire and general practitioner charts.
Study participants had a German nationality. The study was approved by the local ethics committee. Participation was voluntary, and each subject gave written, informed consent. Laboratory analysis. Blood was drawn under standardized conditions, samples were stored at Ϫ80°C until analysis. Lipid serum levels (total cholesterol, HDL cholesterol, low-density lipoprotein [LDL] cholesterol, and triglycerides) were determined immediately, and apolipoprotein A-I and B-100 concentrations by an immunoturbidometric assay (Tina-quant, Roche Diagnostics, Mannheim, Germany). C-reactive protein was measured by a highly sensitive, latex particle-enhanced immunoassay (Roche Diagnostics). The CETP activity was measured by a fluorescence method (Roar Biomedical, Inc., New York, New York). All information for genotyping can be obtained at our Internet site (http://www.genecanvas.org). Statistical analysis. Hardy-Weinberg equilibrium was tested by the chi-square test with one degree of freedom. Linkage disequilibrium between the two polymorphisms was estimated by log-linear analysis (18) and was expressed by the standardized coefficient D'. The association between CETP genotypes and lipid levels was tested by analysis of variance, comparing the mean values of lipids across genotypes. For the association of prospective outcome with genotype, a first combined cardiovascular end point, including death from cardiovascular causes, nonfatal MI, and nonfatal stroke, was considered. Because the association appeared mainly driven by cardiovascular mortality, further survival analyses focused on cardiovascular mortality and data on patients who died of other causes were censored at the time of death. The cumulative survival plot in relation to CETP genotypes was estimated by the Kaplan-Meier method with the use of the log-rank test. Hazard risk ratios (HRRs) of future cardiovascular mortality, according to CETP polymorphisms, were estimated by Cox regression analysis. The interaction between the CETP/C-629A polymorphism and statin treatment on cardiovascular mortality was tested by introducing a corresponding interaction term in the Cox model. In survival analyses, the p value associated
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CAD ϭ coronary artery disease CETP ϭ cholesteryl ester transfer protein CI ϭ confidence interval HDL ϭ high-density lipoprotein HRR ϭ hazard risk ratio LDL ϭ low-density lipoprotein MI ϭ myocardial infarction RCT ϭ reverse cholesterol transport VLDL ϭ very-low-density lipoprotein with genotype was obtained assuming a co-dominant allele effect (genotype entered as an ordinal variable 0, 1, or 2), as this genetic model appeared to fit well with the data. A value of p Ͻ 0.05 was considered to be significant. All computations were carried out with SPSS, version 10.07 (SPSS Inc., Chicago, Illinois).
RESULTS
Characteristics of study population according to clinical outcome. The mean age of the entire study population was 61.5 Ϯ 10.2 years; 76.1% were male patients. Table 1 shows the patients' characteristics according to clinical outcome.
CETP genotypes and intermediate lipid phenotypes.
The genotype distribution for CETP/C-629A significantly deviated from the Hardy-Weinberg expectations (p ϭ 0.008) due to a deficit of homozygotes. Because the cohort was composed of patients with CAD, this result might be explained by a lower frequency than that expected of the AA genotype, as already reported in patients with CAD (13). To check this hypothesis, we compared the genotype frequencies of this cohort with those of a control sample of 574 German individuals recruited at the same time as the cohort (19) . The frequencies of the CC, CA, and AA genotypes were 30.8%, 51.7%, and 17.4%, respectively, in the control sample (p ϭ 0.20 for the Hardy-Weinberg equilibrium test), compared with 36.9%, 50.6%, and 12.5%, respectively, in the CAD cohort (p ϭ 0.004 for the genotype difference between groups), confirming the lower frequency of the AA genotype in this CAD cohort. The genotype distribution for CETP/I405V was compatible with the Hardy-Weinberg expectations (p ϭ 0.21) and did not differ from that of the control group (p ϭ 0.78). Both polymorphisms were in moderate linkage disequilibrium CABG ϭ coronary artery bypass graft surgery; CAD ϭ coronary artery disease; CETP ϭ cholesteryl ester transfer protein; CV ϭ cardiovascular; HDL and LDL ϭ high-and low-density lipoprotein, respectively; hs-CRP ϭ high sensitive C-reactive protein; MI ϭ myocardial infarction; PTCA ϭ percutaneous transluminal coronary angioplasty.
1985
The two polymorphisms influenced HDL cholesterol and CETP activity levels, with the Ϫ629A and the 405V alleles being associated with both an increase in HDL cholesterol and a decrease in CETP activity in a co-dominant fashion ( Table 2) . CETP genotypes and clinical outcome. A significant association was found between the CETP/C-629A polymorphism and the combined cardiovascular end point (Table 3) . Carriers of the Ϫ629A allele had a reduced risk compared with CC homozygotes (p ϭ 0.032). This association was mainly driven by cardiovascular mortality (p Ͻ 0.0001), with no effect observed for nonfatal MI or stroke (Table 3) . There was also a borderline association of this polymorphism with noncardiovascular mortality (p ϭ 0.045), but the number of deaths was small. The association between the CETP/I405V polymorphism and the combined cardiovascular end point did not reach statistical significance. However, as for the CETP/C-629A polymorphism, there was a significant association with cardiovascular mortality (Table 3 ). Further survival analyses focused then on cardiovascular mortality. The relationship between genotypes and cardiovascular mortality was illustrated in the Cox survival plot (Fig. 1) . Multivariate analyses. To explore whether CETP genotypes predicted future fatal cardiovascular events independent of most significant clinical and therapeutic confounders, several models were fitted (Table 4 ). Despite the effect of the CETP/C-629A polymorphism on HDL cholesterol and CETP activity, inclusion of these variables in different models hardly modified the association of genotype with clinical outcome. Similar results were observed with the CETP/I405V genotype, although the association was weaker and lost significance after adjustment for CETP activity (Table 4 ). In a model including both polymorphisms, only the CETP/C-629A polymorphism remained significantly associated with clinical outcome. Assuming a co-dominant allele effect on risk, the HRR associated with the Ϫ629A allele was 0.51 (95% confidence interval [CI] 0.35 to 0.75; p Ͻ 0.001), and the HRR associated with the 405V allele was 0.71 (95% CI 0.48 to 1.06; p ϭ 0.10) in a model including the two polymorphisms simultaneously. The protective effect of the Ϫ629A allele on cardiovascular mortality was of a similar magnitude in stable patients (HRR 0.48, 95% CI 0.31 to 0.73; p Ͻ 0.001) and in patients with acute coronary syndrome (HRR 0.53, 95% CI 0.25 to 1.12; p Ͻ 0.10) (p ϭ 0.85 for homogeneity of the effect). Benefit of statin therapy according to CETP/C-629A genotype. A significant interaction between the CETP/C-629A genotype and statin treatment on cardiovascular mortality was observed. Actually, the benefit of statin therapy was restricted to patients homozygous for the Ϫ629C allele. In these patients, mortality was divided by half in those taking statin medication, whereas no difference was observed in patients carrying the Ϫ629A allele (Table 5 , Fig.  2 ). The same trend was observed with the CETP/I405V polymorphism, but the interaction did not reach statistical significance.
DISCUSSION
This prospective study, based on a large cohort of German patients with documented CAD, confirmed that the CETP/ C-629A polymorphism influenced CETP activity and HDL cholesterol levels and, more importantly, demonstrated, for the first time, that the Ϫ629A allele was associated with a strong protective effect on future cardiovascular mortality. Despite heterogeneity in clinical presentation and pathophysiology, this association was present in all subgroups evaluated and remained highly significant even after controlling for most potential confounders, including the strong predictors of age and ejection fraction. Furthermore, the CETP/C-629A polymorphism appeared to modulate the long-term clinical benefit of statin therapy.
CETP was originally identified as a factor promoting the transfer of cholesteryl esters from HDL to very-low-density lipoprotein (VLDL) and LDL in exchange for triglycerides (20, 21) . As a result of increasing VLDL/LDL cholesterol concentrations and decreasing HDL cholesterol concentrations, CETP has often been considered as being "proatherogenic." On the other hand, CETP is postulated to be a direct (22) and indirect (5) mediator in RCT and should, therefore, also be considered as "anti-atherogenic."
An interesting window to elucidate the role of CETP in atherosclerosis is provided by genetic studies. A common TaqIB polymorphism located in intron 1 of the CETP gene has been shown in several studies to be associated with variations in CETP mass or activity and HDL cholesterol. A protective effect of the B2 allele of this polymorphism on the risk of CAD has been reported (10, 23) . Furthermore, in the REgression GRowth Evaluation Statin Study (REGRESS) clinical trial on pravastatin, the B2 allele was reported to slow down the progression of coronary atherosclerosis in patients receiving a placebo, whereas no effect Blankenberg et al. June 4, 2003 June 4, :1983 CETP Gene Variation and Prognosis was observed in statin-treated patients (16) . However, the TaqIB polymorphism has no functional role by itself, and other polymorphisms in linkage disequilibrium with it should be responsible for the observed effects. A polymorphism at position Ϫ629 in the promoter of the CETP gene was in nearly complete association with the TaqIB polymorphism. It was further shown that the Ϫ629A allele, which is almost completely concordant with the B2 allele, displayed a lower promoter activity than the Ϫ629C allele, supporting the notion that this polymorphism might be responsible, at least partly, for the effects initially observed with the TaqIB polymorphism (14) . In the present study, the TaqIB polymorphism was also genotyped, but we did not report the results because of the redundancy due to strong linkage disequilibrium with the C-629A polymorphism. The effects of the CETP/I405V mutation on CETP activity and HDL cholesterol were in accordance with earlier studies (9, 24, 25) . However, these effects appeared to be mainly explained by its linkage disequilibrium with the C-629A polymorphism. The two polymorphisms included in the present study were selected on the basis of their potential functionality, their relatively high frequency, and their strong effects on HDL and CETP concentrations (13) . However, other polymorphisms might also be of interest, in particular, two less frequent coding polymorphisms: A373P and R451Q. In the future, haplotype analyses should be developed to evaluate the impact of all CETP gene polymorphisms on prospective outcome. In the present study, the mechanism relating CETP genotype to cardiovascular risk appeared rather independent of HDL cholesterol and CETP concentrations. However, it should be stressed that the association of CETP genotype with HDL cholesterol in this cohort of patients with CAD was weaker than that generally reported in apparently healthy subjects (9, 10, 24) , and unlike previous studies, we did not find any association with apolipoprotein A-I levels. One explanation might be that lipid/lipoprotein levels in this cohort of patients are not relevant intermediate phenotypes because of modifications induced by treatment or disease. It might also be speculated that the impact of genotype on risk is rather mediated by a local effect of CETP within the vessel wall.
One additional finding of our study was the interaction between the CETP/C-629A polymorphism and statin therapy on clinical outcome, with the beneficial effect of statin therapy regarding future cardiovascular mortality being restricted to CC homozygotes. Which putative mechanisms might explain the relationship between the CETP/C-629A polymorphism and long-term response to statin treatment? The CC homozygotes have a stronger promoter activity and exhibit the highest CETP expression level (14) . Atorvastatin, which was the most frequently prescribed statin in our study, has been shown to decrease cholesteryl ester transport from the protective HDL to the highly pro-atherogenic VLDL subfraction and to decrease CETP activity (26) . This reduced cholesteryl ester transport from HDL to VLDL, which appears as an important mechanism to lower LDL cholesterol, might be enhanced in CC homozygotes, explaining why these subjects benefit most from (atorva)statin therapy.
Some limitations of the present study must be stressed. The AtheroGene study is not a prospectively randomized statin-placebo trial. Moreover, we did not have the ability to evaluate lipid parameters before and after statin therapy. The results on the genotype-statin interaction should then be considered as hypothesis-generating. Because we tested several primary and secondary hypotheses that were not independent, it was not possible to correct for multiple testing; hence, the p values provided are nominal and 
